$阿玛琳(AMRN)$
U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication 
For best results when printing this announcement, please click on link below: 
网页链接 


 - PDUFA date assigned is September 28, 2019, four months sooner than 
expected 
 - Vascepa, assuming approval, will be first drug indicated to reduce 
residual cardiovascular risk in patients with statin-managed LDL-C 
cholesterol, but persistent elevated triglycerides, as studied in the landmark 
REDUCE-IT™ cardiovascular outcomes study